Showing 1-10 of 1170 results for "".
Systemic Disease and the Eye: Risks and Recommendations
https://modernod.com/topics/retina/systemic-disease-and-the-eye-risks-and-recommendations/48718/A guide to understanding the ocular complications of metabolic syndrome.Researchers Tackle AMD with Hyperthermia
https://modernod.com/articles/significant-findings/researchers-tackle-amd-with-hyperthermia/48733/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuVision Difficulties Linked With Anxiety, Depression
https://modernod.com/articles/significant-findings/vision-difficulties-linked-with-anxiety-depression/39899/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuOpposition Mounts Against Tariffs on Optical Products
https://modernod.com/articles/significant-findings/opposition-mounts-against-tariffs-on-optical-products/39901/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuNew Data Reveal Diabetes Affects Corneal Thickness
https://modernod.com/articles/significant-findings/new-data-reveal-diabetes-affects-corneal-thickness/48883/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuInterventional Glaucoma and the OD’s Role
https://modernod.com/topics/glaucoma/interventional-glaucoma-and-the-ods-role/54344/New therapies are helping us manage patients better than ever before.New Therapy for Sjögren Disease on the Horizon
https://modernod.com/articles/significant-findings/new-therapy-for-sjogren-disease-on-the-horizon/45564/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuA Special Farewell
https://modernod.com/editorial-series/significant-findings/a-special-farewell/51491/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuOphthalmic Ointment for DED Moving Toward NDA Submission
https://modernod.com/editorial-series/significant-findings/ophthalmic-ointment-for-ded-moving-toward-nda-submission/49220/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuViaLase Launches Clinical Trial for Incision-Free Glaucoma Procedure
https://modernod.com/articles/significant-findings/vialase-launches-clinical-trial-for-incision-free-glaucoma-procedure/49095/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cu
- Prev
- Next
